公开(公告)号：EP1833816B1

公开(公告)日：2009-11-11

申请号：EP05820552.7

申请日：2005-12-28

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： BREITENSTEIN, Werner ,  EHARA, Takeru Novartis Pharma K.K. ,  EHRHARDT, Claus ,  GROSCHE, Philipp ,  HITOMI, Yuko Novartis Pharma K.K. ,  IWAKI, Yuki Novartis Pharma K.K. ,  KANAZAWA, Takanori Novartis Pharma K.K. ,  KONISHI, Kazuhide Novartis Pharma K.K. ,  MAIBAUM, Juergen, Klaus ,  MASUYA, Keiichi ,  NIHONYANAGI, Atsuko Novartis Pharma K.K. ,  OSTERMANN, Nils ,  SUZUKI, Masaki Novartis Pharma K.K. ,  TOYAO, Atsushi Novartis Pharma K.K. ,  YOKOKAWA, Fumiaki Novartis Pharma K.K.

IPC分类号： C07D401/10 ,  C07D401/12 ,  C07D413/12 ,  C07D413/04 ,  C07D409/12 ,  C07D405/12 ,  C07D409/10 ,  C07D401/14 ,  C07D417/12 ,  C07D413/14 ,  C07D471/04 ,  A61K31/4545 ,  A61P9/00

CPC分类号： C07D471/04 ,  C07D211/60 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/10 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

摘要： 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4­substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.

公开(公告)号：EP1833816A1

公开(公告)日：2007-09-19

申请号：EP05820552.7

申请日：2005-12-28

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： BREITENSTEIN, Werner ,  EHARA, Takeru Novartis Pharma K.K. ,  EHRHARDT, Claus ,  GROSCHE, Philipp ,  HITOMI, Yuko Novartis Pharma K.K. ,  IWAKI, Yuki Novartis Pharma K.K. ,  KANAZAWA, Takanori Novartis Pharma K.K. ,  KONISHI, Kazuhide Novartis Pharma K.K. ,  MAIBAUM, Juergen, Klaus ,  MASUYA, Keiichi ,  NIHONYANAGI, Atsuko Novartis Pharma K.K. ,  OSTERMANN, Nils ,  SUZUKI, Masaki Novartis Pharma K.K. ,  TOYAO, Atsushi Novartis Pharma K.K. ,  YOKOKAWA, Fumiaki Novartis Pharma K.K.

IPC分类号： C07D401/10 ,  C07D401/12 ,  C07D413/12 ,  C07D413/04 ,  C07D409/12 ,  C07D405/12 ,  C07D409/10 ,  C07D401/14 ,  C07D417/12 ,  C07D413/14 ,  C07D471/04 ,  A61K31/4545 ,  A61P9/00

CPC分类号： C07D471/04 ,  C07D211/60 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/10 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

摘要： 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4­substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.